|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Plague | |||||
| 2 | More general conditions related to this trial | ||||
| Bacterial Infections | |||||
| Enterobacteriaceae Infections | |||||
| Gram-Negative Bacterial Infections | |||||
| Yersinia Infections | |||||
| 3 | Interventions listed in this trial | ||||
| Alhydrogel | |||||
| rF1 and rV protein antigens | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Aluminum Hydroxide | |||||
| 5 | More general drug interventions related to this trial | ||||
| Adjuvants, Immunologic | |||||
| Antacids | |||||
| Immunologic Factors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| 6 | Sponsors listed in this trial | ||||
| PharmAthene UK Limited | |||||
| National Institute of Allergy and Infectious Diseases (NIAID) | |||||